Can UCB Make Its Mark In Myasthenia Gravis?
Playing Catch-Up With Alexion And Argenx
The Belgian drugmaker has presented positive data on its two submission-ready generalized myasthenia gravis drugs zilucoplan and rozanolixizumab but analysts are concerned that their efficacy will not differentiate them sufficiently to challenge Vyvgart and Soliris/Ultomiris.
